Jeremy Bost
Head of Clinical Affairs
Ascilion
Biography
Jeremy Bost, Ph.D. is the Head of Clinical Affairs at Ascilion, an emerging medical device company based in Stockholm Sweden. Ascilion currently has customers using the miconeedle-based PELSA system in 12 countries on 5 continents, and has been involved in over 20 clinical studies to date. Dr. Bost has worked in translational and clinical research with a focus in dermatology and medical devices.
Conference
Day 1
Session 1: Hormones influence on Skin & Hair
Dermal Interstitial Fluid: Pain- Free Sampling of Molecular Biomarkers in
Clinical Studies
Dermal interstitial fluid (dISF) is a highly-concentrated biofluid that surrounds cells in skin tissue. dISF is highly concentrated in molecular biomarkers and therefore comprises a novel alternative for biomarker analysis to blood or skin biopsy, enabling higher patient comfort and continuous biomarker monitoring. Ascilion has developed a system utilizing hollow microneedles and gentle subpressure application, capable of sampling dISF in a pain-free manner. Importantly, the volumes of dISF sampled are useful for high-sensitivity molecular assays and biomarkers panels. Interestingly, biomarker species quantifiable in dISF include dermal inflammation markers, skin barrier and health markers, hormones, lipids, and both endogenous and exogenous (bacterial) metabolites.